

Pharmaceutical company Indivior reported a drop in first-quarter net revenue but impressed with results of trials for its new treatment for schizophre...


Indivior topped the risers despite pre-tax profit dipping in the first quarter, as its RBP-7000 schizophrenia drug met the primary and secondary endpo...